SHPH
Shuttle Pharmaceuticals Holdings, Inc.
Drug Manufacturers - Specialty & Generic
Market Cap$4M
5Y Perf.-100.0%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
SHPH vs ATNM
Revenue, margins, valuation, and 5-year total return — side by side.
ATNM
Actinium Pharmaceuticals, Inc.
Biotechnology
Market Cap$38M
5Y Perf.-82.6%
SHPH vs ATNM — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | SHPH | ATNM |
|---|---|---|
| Industry | Drug Manufacturers - Specialty & Generic | Biotechnology |
| Market Cap | $4M | $38M |
| Revenue (TTM) | $0.00 | $90K |
| Net Income (TTM) | $-11M | $-35M |
| Gross Margin | — | -8.1% |
| Operating Margin | — | -414.9% |
| Total Debt | $1M | $2M |
| Cash & Equiv. | $2M | $73M |
SHPH vs ATNM — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
SHPH
ATNM
| Stock | Aug 22 | May 26 | Return |
|---|---|---|---|
| Shuttle Pharmaceuti… (SHPH) | 100 | 0.0 | -100.0% |
| Actinium Pharmaceut… (ATNM) | 100 | 17.4 | -82.6% |
Price return only. Dividends and distributions are not included.
Quick Verdict: SHPH vs ATNM
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: SHPH leads in 3 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. Actinium Pharmaceuticals, Inc. is the stronger pick specifically for recent price momentum and sentiment and operational efficiency and capital deployment. As sector peers, any of these can serve as alternatives in the same allocation.
SHPH
Shuttle Pharmaceuticals Holdings, Inc.
The Income Pick
SHPH carries the broadest edge in this set and is the clearest fit for income & stability and sleep-well-at-night.
- beta 1.24
- Lower volatility, beta 1.24, current ratio 1.44x
- Beta 1.24, current ratio 1.44x
Best for: income & stability and sleep-well-at-night
ATNM
Actinium Pharmaceuticals, Inc.
The Growth Play
ATNM is the clearest fit if your priority is growth exposure and long-term compounding.
- Rev growth -100.0%, EPS growth 30.6%
- -97.7% 10Y total return vs SHPH's -100.0%
- -12.9% vs SHPH's -89.1%
Best for: growth exposure and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | SHPH | -16.6% revenue growth vs ATNM's -100.0% |
| Quality / Margins | SHPH | -52.7% margin vs ATNM's -384.4% |
| Stability / Safety | SHPH | Beta 1.24 vs ATNM's 1.40 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | ATNM | -12.9% vs SHPH's -89.1% |
| Efficiency (ROA) | ATNM | -52.3% ROA vs SHPH's -253.9% |
SHPH vs ATNM — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2023
SHPH vs ATNM — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLATNMLAGGINGSHPH
SHPHShuttle Pharmaceutica…
0leads
ATNMActinium Pharmaceutic…
4leads
6 Total Categories
CATEGORYLEADERvs SHPHMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
ATNM1/1
Valuation MetricsMultiples, price ratios, and targets
ATNM2/2
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
ATNM6/7
Total Returns1Y, 3Y, 5Y total returns with dividends
ATNM6/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
ATNM leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
ATNM and SHPH operate at a comparable scale, with $90,000 and $0 in trailing revenue.
| Metric | SHPHShuttle Pharmaceu… | ATNMActinium Pharmace… |
|---|---|---|
| RevenueTrailing 12 months | $0 | $90,000 |
| EBITDAEarnings before interest/tax | -$11M | -$37M |
| Net IncomeAfter-tax profit | -$11M | -$35M |
| Free Cash FlowCash after capex | -$11M | -$25M |
| Gross MarginGross profit ÷ Revenue | — | -8.1% |
| Operating MarginEBIT ÷ Revenue | — | -414.9% |
| Net MarginNet income ÷ Revenue | — | -384.4% |
| FCF MarginFCF ÷ Revenue | — | -278.2% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | -183.8% | +56.8% |
ATNM leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
ATNM leads this category, winning 2 of 2 comparable metrics.
Valuation Metrics
| Metric | SHPHShuttle Pharmaceu… | ATNMActinium Pharmace… |
|---|---|---|
| Market CapShares × price | $4M | $38M |
| Enterprise ValueMkt cap + debt − cash | $3M | -$33M |
| Trailing P/EPrice ÷ TTM EPS | -0.00x | -0.96x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | — |
| Price / BookPrice ÷ Book value/share | 10.28x | 1.12x |
| Price / FCFMarket cap ÷ FCF | — | — |
ATNM leads this category, winning 2 of 2 comparable metrics.
Profitability & Efficiency
ATNM leads this category, winning 6 of 7 comparable metrics.
Profitability & Efficiency
ATNM delivers a -151.7% return on equity — every $100 of shareholder capital generates $-152 in annual profit, vs $-5 for SHPH. ATNM carries lower financial leverage with a 0.05x debt-to-equity ratio, signaling a more conservative balance sheet compared to SHPH's 1.65x. On the Piotroski fundamental quality scale (0–9), ATNM scores 3/9 vs SHPH's 2/9, reflecting mixed financial health.
| Metric | SHPHShuttle Pharmaceu… | ATNMActinium Pharmace… |
|---|---|---|
| ROE (TTM)Return on equity | -4.8% | -151.7% |
| ROA (TTM)Return on assets | -2.5% | -52.3% |
| ROICReturn on invested capital | -4.6% | — |
| ROCEReturn on capital employed | -2.6% | -59.5% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 3 |
| Debt / EquityFinancial leverage | 1.65x | 0.05x |
| Net DebtTotal debt minus cash | -$746,672 | -$71M |
| Cash & Equiv.Liquid assets | $2M | $73M |
| Total DebtShort + long-term debt | $1M | $2M |
| Interest CoverageEBIT ÷ Interest expense | -50.60x | — |
ATNM leads this category, winning 6 of 7 comparable metrics.
Total Returns (Dividends Reinvested)
ATNM leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ATNM five years ago would be worth $1,674 today (with dividends reinvested), compared to $1 for SHPH. Over the past 12 months, ATNM leads with a -12.9% total return vs SHPH's -89.1%. The 3-year compound annual growth rate (CAGR) favors ATNM at -47.9% vs SHPH's -86.0% — a key indicator of consistent wealth creation.
| Metric | SHPHShuttle Pharmaceu… | ATNMActinium Pharmace… |
|---|---|---|
| YTD ReturnYear-to-date | -61.0% | -10.9% |
| 1-Year ReturnPast 12 months | -89.1% | -12.9% |
| 3-Year ReturnCumulative with dividends | -99.7% | -85.9% |
| 5-Year ReturnCumulative with dividends | -100.0% | -83.3% |
| 10-Year ReturnCumulative with dividends | -100.0% | -97.7% |
| CAGR (3Y)Annualised 3-year return | -86.0% | -47.9% |
ATNM leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
Evenly matched — SHPH and ATNM each lead in 1 of 2 comparable metrics.
Risk & Volatility
SHPH is the less volatile stock with a 1.24 beta — it tends to amplify market swings less than ATNM's 1.40 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ATNM currently trades 62.6% from its 52-week high vs SHPH's 6.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | SHPHShuttle Pharmaceu… | ATNMActinium Pharmace… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.24x | 1.40x |
| 52-Week HighHighest price in past year | $11.25 | $1.95 |
| 52-Week LowLowest price in past year | $0.50 | $0.95 |
| % of 52W HighCurrent price vs 52-week peak | +6.3% | +62.6% |
| RSI (14)Momentum oscillator 0–100 | 43.3 | 52.8 |
| Avg Volume (50D)Average daily shares traded | 840K | 184K |
Evenly matched — SHPH and ATNM each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | SHPHShuttle Pharmaceu… | ATNMActinium Pharmace… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | — |
| Price TargetConsensus 12-month target | — | — |
| # AnalystsCovering analysts | — | — |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | 0 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
ATNM leads in 4 of 6 categories — strongest in Income & Cash Flow and Valuation Metrics. 1 category is tied.
Best OverallActinium Pharmaceuticals, I… (ATNM)Leads 4 of 6 categories
Loading custom metrics...
SHPH vs ATNM: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Which is the better long-term investment — SHPH or ATNM?
Over the past 5 years, Actinium Pharmaceuticals, Inc.
(ATNM) delivered a total return of -83. 3%, compared to -100. 0% for Shuttle Pharmaceuticals Holdings, Inc. (SHPH). Over 10 years, the gap is even starker: ATNM returned -97. 7% versus SHPH's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
02Which is safer — SHPH or ATNM?
By beta (market sensitivity over 5 years), Shuttle Pharmaceuticals Holdings, Inc.
(SHPH) is the lower-risk stock at 1. 24β versus Actinium Pharmaceuticals, Inc. 's 1. 40β — meaning ATNM is approximately 13% more volatile than SHPH relative to the S&P 500. On balance sheet safety, Actinium Pharmaceuticals, Inc. (ATNM) carries a lower debt/equity ratio of 5% versus 165% for Shuttle Pharmaceuticals Holdings, Inc. — giving it more financial flexibility in a downturn.
03Which is growing faster — SHPH or ATNM?
On earnings-per-share growth, the picture is similar: Actinium Pharmaceuticals, Inc.
grew EPS 30. 6% year-over-year, compared to -2159. 3% for Shuttle Pharmaceuticals Holdings, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
04Which has better profit margins — SHPH or ATNM?
Shuttle Pharmaceuticals Holdings, Inc.
(SHPH) is the more profitable company, earning 0. 0% net margin versus -384. 4% for Actinium Pharmaceuticals, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: SHPH leads at 0. 0% versus -414. 9% for ATNM. At the gross margin level — before operating expenses — SHPH leads at 0. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — SHPH or ATNM?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
06Is SHPH or ATNM better for a retirement portfolio?
For long-horizon retirement investors, Shuttle Pharmaceuticals Holdings, Inc.
(SHPH) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 24)). Both have compounded well over 10 years (SHPH: -100. 0%, ATNM: -97. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between SHPH and ATNM?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.